You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Références<br />
53. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006<br />
Feb;43(2 Suppl 1):S99-S112.<br />
54. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b<br />
plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a<br />
randomised trial. Lancet. 2001 Sep 22;358(9286):958-65.<br />
55. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonca<strong>le</strong>s FL, Jr., et al. Peginterferon alfa-2a plus<br />
ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002 Sep 26;347(13):975-82.<br />
56. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, et al. Impact of pegylated interferon<br />
alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology. 2002<br />
May;122(5):1303-13.<br />
57. Kurokawa M, Hiramatsu N, Oze T, Mochizuki K, Yakushijin T, Kurashige N, et al. Effect of interferon alpha-<br />
2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with chronic hepatitis. Hepatol<br />
Res. 2009 May;39(5):432-8.<br />
58. Nishiguchi S, Shiomi S, Nakatani S, Takeda T, Fukuda K, Tamori A, et al. Prevention of hepatocellular<br />
carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet. 2001 Jan 20;357(9251):196-7.<br />
59. Singal AK, Singh A, Jaganmohan S, Guturu P, Mummadi R, Kuo YF, et al. Antiviral therapy reduces risk of<br />
hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol. 2009<br />
Oct 29.<br />
60. Stap<strong>le</strong>s CT, Jr., Rimland D, Dudas D. Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A.<br />
(Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival. Clin Infect<br />
Dis. 1999 Jul;29(1):150-4.<br />
61. Rockstroh JK, Mocroft A, Soriano V, Tural C, Losso MH, Horban A, et al. Influence of hepatitis C virus<br />
infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis. 2005<br />
Sep 15;192(6):992-1002.<br />
62. Cacoub P, Geffray L, Rosenthal E, Perronne C, Veyssier P, Raguin G. Mortality among human<br />
immunodeficiency virus-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus<br />
in French Departments of Internal Medicine/Infectious Diseases, in 1995 and 1997. Clin Infect Dis. 2001 Apr<br />
15;32(8):1207-14.<br />
63. Rosenthal E, Poiree M, Pradier C, Perronne C, Salmon-Ceron D, Geffray L, et al. Mortality due to hepatitis<br />
C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). Aids. 2003 Aug<br />
15;17(12):1803-9.<br />
64. Salmon-Ceron D, Lewden C, Morlat P, Bevilacqua S, Jougla E, Bonnet F, et al. Liver disease as a major<br />
cause of death among HIV infected patients: ro<strong>le</strong> of hepatitis C and B viruses and alcohol. J Hepatol. 2005<br />
Jun;42(6):799-805.<br />
65. Lewden C, May T, Rosenthal E, Burty C, Bonnet F, Costagliola D, et al. Changes in causes of death among<br />
adults infected by HIV between 2000 and 2005: The "Mortalite 2000 and 2005" surveys (ANRS EN19 and<br />
Mortavic). J Acquir Immune Defic Syndr. 2008 Aug 15;48(5):590-8.<br />
66. Salmon-Ceron D, Rosenthal E, Lewden C, Bouteloup V, May T, Burty C, et al. Emerging ro<strong>le</strong> of<br />
hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: The French national<br />
Mortalite 2005 study. J Hepatol. 2009 Apr;50(4):736-45.<br />
67. Rosenthal E, Salmon-Ceron D, Lewden C, Bouteloup V, Pialoux G, Bonnet F, et al. Liver-related deaths in<br />
HIV-infected patients between 1995 and 2005 in the French GERMIVIC Joint Study Group Network<br />
(Mortavic 2005 study in collaboration with the Mortalite 2005 survey, ANRS EN19). HIV Med. 2009<br />
May;10(5):282-9.<br />
68. Martinez E, Milinkovic A, Buira E, de Lazzari E, Leon A, Larrousse M, et al. Incidence and causes of death<br />
in HIV-infected persons receiving highly active antiretroviral therapy compared with estimates for the general<br />
population of similar age and from the same geographical area. HIV Med. 2007 May;8(4):251-8.<br />
69. Weber R, Sabin CA, Friis-Mol<strong>le</strong>r N, Reiss P, El-Sadr WM, Kirk O, et al. Liver-related deaths in persons<br />
infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med. 2006 Aug 14-<br />
28;166(15):1632-41.<br />
70. Soto B, Sanchez-Quijano A, Rodrigo L, del Olmo JA, Garcia-Bengoechea M, Hernandez-Quero J, et al.<br />
Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired<br />
hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol. 1997 Jan;26(1):1-5.<br />
71. Pol S, Fontaine H, Carnot F, Zylberberg H, Berthelot P, Brechot C, et al. Predictive factors for development<br />
of cirrhosis in parenterally acquired chronic hepatitis C: a comparison between immunocompetent and<br />
immunocompromised patients. J Hepatol. 1998 Jul;29(1):12-9.<br />
72. Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, et al. Liver fibrosis progression in<br />
human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology.<br />
1999 Oct;30(4):1054-8.<br />
73. Eyster ME, Diamondstone LS, Lien JM, Ehmann WC, Quan S, Goedert JJ. Natural history of hepatitis C<br />
virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus.<br />
The Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr. 1993 Jun;6(6):602-10.<br />
179
Change language